Li Chunzheng, Wang Xinzheng, Wu Shengming, Zhao Junqing, Fang Junjian, Li Hui, Zhu Yingjie, Zhang Kang, Peng Jing, Mao Jie, Li Weihua, He Kun, Wang Na, Dong Fangting
National Center of Biomedical Analysis, Beijing, 100039, China.
Heliyon. 2023 Apr 12;9(4):e15418. doi: 10.1016/j.heliyon.2023.e15418. eCollection 2023 Apr.
A novel vardenafil analogue was identified in dietary supplement as an adulterant in herbal formulations. The structure of this analogue was elucidated using HRMS, NMR after extraction from the pulverized powder. It was named morphardenafil as a morpholine ring has replaced the -ethyl piperazine ring in vardenafil. A tablet of this dietary supplement contained about 50 mg of unspecified morphardenafil, which is 2.5 - 20-times the prescriptive dosage of Levetra, the commercial formulation of the vardenafil monohydrochloride salt in the market and probably places unwary consumers at risk for potentially serious adverse effects or drug-drug interaction (DDI).
在膳食补充剂中发现一种新型伐地那非类似物，它是草药制剂中的掺假物。从粉碎的粉末中提取后，利用高分辨率质谱（HRMS）和核磁共振（NMR）对该类似物的结构进行了阐明。因其吗啉环取代了伐地那非中的 - 乙基哌嗪环，故将其命名为吗啉代伐地那非。这种膳食补充剂的一片药片中含有约50毫克未明确的吗啉代伐地那非，这是市场上盐酸伐地那非商业制剂艾力达（Levetra）规定剂量的2.5至20倍，可能会使粗心的消费者面临潜在严重不良反应或药物相互作用（DDI）的风险。
